Proton Pump Inhibitors in the COVID-19 Pandemic
The safety of proton pump inhibitors (PPIs) use in coronavirus infection (COVID-19) is not well understood. PPIs are potent suppressors of gastric secretion and become one of the ten most widely used drugs in the world. They are expected to influence virus susceptibility, severity, and outcomes in p...
Saved in:
Main Authors: | T. E. Kugler, I. S. Malovichko, V. B. Gnilitskaya, A. L. Khristulenko, N. F. Yarovaya |
---|---|
Format: | Article |
Language: | Russian |
Published: |
SINAPS LLC
2022-08-01
|
Series: | Архивъ внутренней медицины |
Subjects: | |
Online Access: | https://www.medarhive.ru/jour/article/view/1477 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Proton Pump Inhibitors and Gastric Cancer
by: Seungkyung Kang, et al.
Published: (2021-09-01) -
Gastroesophageal reflux disease, resistant to proton pump inhibitors
by: V. O. Kaybysheva, et al.
Published: (2011-06-01) -
Clinical Significance of Changes in Gut Microbiome Associated with Use of Proton Pump Inhibitors
by: Tae Jun Kim, et al.
Published: (2020-09-01) -
Proton-pump Inhibitors and the Risk of Dementia: A Systematic Review and Meta-analysis
by: Kyu-Tae Yoon, et al.
Published: (2021-06-01) -
Risk of Bacterial Infection from Proton Pump Inhibitor Use
by: Sung Soo Kim, et al.
Published: (2017-06-01)